Table 4.
Ingenuity pathway analysis of pathways induced in reactive astrocytes
| Ingenuity canonical pathways | p value | Genes |
|---|---|---|
| Pathways induced in astrocytes after MCAO | ||
| Acute phase response signaling | 1.66E-08 | SERPING1, SAA1, SERPINF2, IL6R, C4B, STAT3, HMOX1, OSMR, C1R, NRAS, NFKBIE, KRAS, SERPINE1, IL6, MYD88, TNFRSF1A, A2M, IL1RAP, IL1R1, SERPINA3, CEBPB, C1S, SOCS5, RRAS2, SOCS3, CP, C3, HPX |
| IL-6 signaling | 1.45E-05 | TNFRSF1A, A2M, IL1RAP, IL6R, IL1R1, STAT3, CEBPB, TNFAIP6, HSPB1, CD14, RRAS2, NRAS, NFKBIE, MAP4K4, KRAS, IL6 |
| Hepatic fibrosis/hepatic stellate cell activation | 4.27E-05 | FAS, TNFRSF1A, A2M, ICAM1, IL1RAP, IL6R, IL1R1, CTGF, TLR4, CD14, TIMP1, MYL9, CXCL3, MYH9, CSF1, IGFBP4, IL6, IGFBP3, MET |
| Role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis | 1.26E-04 | PLCE1, PLCD3, CEBPA, IL6R, CAMK2D, STAT3, C1R, MYC, NRAS, CSF1, NFKBIE, CEBPD, KRAS, IL6, TLR2, ROCK2, MYD88, TNFRSF1A, ICAM1, ATF4, IL1RAP, IL1R1, TLR4, CCND1, CEBPB, C1S, FZD3, RRAS2, ADAMTS4, SOCS3, NFATC2, CEBPG |
| Coagulation system | 2.40E-04 | BDKRB2, SERPINF2, A2M, PLAT, PROS1, PLAUR, SERPINE1, THBD |
| PI3K/AKT signaling | 2.51E-04 | PTGS2, GDF15, PPP2R2A, YWHAG, MCL1, CCND1, HSP90AA1, CDKN1A, RRAS2, EIF4EBP1, GAB2, NRAS, HLA-B, NFKBIE, KRAS, MAP3K8 |
| RAN signaling | 4.57E-04 | IPO5, RANBP1, XPO1, RAN, KPNB1 |
| Germ cell–Sertoli cell junction signaling | 4.79E-04 | ACTN1, RND3, SORBS1, TNFRSF1A, A2M, TUBA1A, IQGAP1, TUBB, TUBA1C, MAP3K6, RRAS2, NRAS, TUBB6, RHOJ, TUBA3E, KRAS, MAP3K8, ZYX |
| ERK5 signaling | 9.33E-04 | FOSL1, RRAS2, MYC, ATF4, YWHAG, NRAS, LIF, KRAS, MAP3K8, RPS6KA3 |
| HGF signaling | 1.23E-03 | PTGS2, CCND1, STAT3, CDKN1A, ELK3, ETS2, MAP3K6, RRAS2, NRAS, KRAS, IL6, MAP3K8, MET |
| Aminosugars metabolism | 1.38E-03 | PDE1B, PDE12, NPL, CYB5R3, PDE4B, HK1, PDE3B, GFPT2, CYB5R1, HK2, HKDC1 |
| 14-3-3-mediated signaling | 1.48E-03 | PLCE1, TNFRSF1A, YWHAG, PLCD3, TUBA1A, TUBB, TUBA1C, RRAS2, NRAS, TUBB6, TUBA3E, GFAP, VIM, KRAS |
| IL-10 signaling | 1.74E-03 | CD14, FCGR2B, SOCS3, IL1RAP, IL1R1, STAT3, MAP4K4, NFKBIE, HMOX1, IL6 |
| p53 signaling | 2.14E-03 | CCNG1, FAS, GADD45G, DRAM1, GNL3, GADD45A, RPRM, THBS1, CCND1, CDKN1A, GADD45B, PERP |
| PI3K signaling in B-lymphocytes | 2.34E-03 | PLCE1, PLCD3, ATF4, IRS2, TLR4, CAMK2D, FCGR2B, RRAS2, C3, NFATC2, NRAS, NFKBIE, ATF5, KRAS, ATF3 |
| Dendritic cell maturation | 3.39E-03 | TLR2, MYD88, TNFRSF1A, HLAC, ICAM1, ATF4, TLR4, COL18A1, FCGR2B, COL5A3, RELB, FSCN1, HLA-B, NFKBIE, IL6 |
| Thyroid cancer signaling | 3.72E-03 | BDNF, RRAS2, CXCL10, MYC, NRAS, CCND1, KRAS |
| Type I diabetes mellitus signaling | 5.13E-03 | SOCS5, FAS, MYD88, TNFRSF1A, SOCS3, HLAC, CASP8, PTPRN, IL1RAP, IL1R1, HLA-B, NFKBIE |
| ILK signaling | 5.37E-03 | ACTN1, RND3, PTGS2, TNFRSF1A, PPP2R2A, ATF4, PARVA, IRS2, CCND1, MYL9, MYC, FLNA, MYH9, RHOJ, VIM, FLNC |
| Oncostatin M signaling | 5.75E-03 | CHI3L1, OSMR, RRAS2, NRAS, STAT3, KRAS |
| Pathways induced in astrocytes after LPS treatment | ||
| Acute phase response signaling | 3.89E-08 | PIK3R1, SERPING1, SAA1, MYD88, A2M, RRAS, IL1R1, SERPINA3, C4B, C1S, OSMR, C1R, FN1, CP, C3, NFKBIE, LBP |
| Antigen presentation pathway | 3.98E-08 | B2M, HLA-C, HLA-E, PSMB9, HLA-B, PSMB8, TAP2, TAPBP |
| Interferon signaling | 1.74E-06 | IFITM1, IRF9, OAS1, IFI35, PSMB8, IFIT3, IFNAR2 |
| Hepatic fibrosis/hepatic stellate cell activation | 2.88E-06 | ICAM1, A2M, SMAD3, IL1R1, IFNAR2, TIMP1, CD14, TGFBR2, FN1, CXCL3, LBP, PGF, MET |
| Virus entry via endocytic pathways | 5.89E-05 | PRKCA, PIK3R1, B2M, HLAC, PRKCD, RRAS, FLNA, HLA-B, CAV1 |
| Glioma invasiveness signaling | 1.12E-04 | TIMP1, F2R, PIK3R1, RHOU, RRAS, RHOJ, CD44 |
| Role of pattern recognition receptors in recognition of bacteria and viruses | 1.20E-04 | IFIH1, PIK3R1, TLR2, MYD88, OAS1, C3, DDX58, PTX3 |
| Protein ubiquitination pathway | 1.26E-04 | USP18, UBE2V2, PSME1, B2M, HLA-C, PSMB9, HSPB8, PSMB10, TAP2, HSPB1, BIRC3, HLA-B, PSMB8, PSMB2, HSPB6 |
| Role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis | 2.09E-04 | PIK3R1, TLR2, MYD88, ICAM1, PRKCD, RRAS, IL1R1, CAMK2D, CCND1, C1S, PRKCA, C1R, FN1, IL17RA, NFKBIE, CEBPD, PGF |
| Complement system | 2.19E-04 | C1S, SERPING1, C1R, C3, C4B |
| OX40 signaling pathway | 4.90E-04 | B2M, HLA-C, HLA-E, HLA-B, NFKBIE |
| Caveolar-mediated endocytosis signaling | 5.13E-04 | PRKCA, FLOT1, B2M, HLA-C, FLNA, HLA-B, CAV1 |
| LPS-stimulated MAPK signaling | 5.62E-04 | CD14, PRKCA, PIK3R1, PRKCD, RRAS, NFKBIE, LBP |
| HGF signaling | 7.76E-04 | PRKCA, PIK3R1, MAP3K6, PRKCD, RRAS, CCND1, CDKN1A, MET |
| Germ cell–Sertoli cell junction signaling | 8.13E-04 | PVRL2, PIK3R1, SORBS1, MAP3K6, TGFBR2, RHOU, A2M, RRAS, RHOJ, GSN |
| HER-2 signaling in breast cancer | 9.12E-04 | NRG1, PRKCA, PIK3R1, PRKCD, RRAS, CCND1, CDKN1A |
| fMLP signaling in neutrophils | 1.23E-03 | PRKCA, PIK3R1, PRKCD, RRAS, ARPC5, NFKBIE, ARPC1B, ITPR1 |
| Allograft rejection signaling | 1.35E-03 | B2M, HLA-C, HLA-E, HLA-B |
| Thrombin signaling | 1.35E-03 | F2R, ADCY9, PRKCA, PIK3R1, RHOU, PRKCD, RRAS, CAMK2D, MYLK, RHOJ, ITPR1 |
| Dendritic cell maturation | 1.58E-03 | PIK3R1, TLR2, RELB, MYD88, B2M, HLA-C, ICAM1, HLA-B, NFKBIE |
Shown are the top 20 canonical pathways identified using Ingenuity Pathway Analysis of genes more than twofold significantly enriched in MCAO and LPS reactive astrocytes. Bold is used for emphasis.